Headlines

Microbiome startup Sequentia Biotech heralds “new era” in omics with €10 million round

The Barcelona-based startup Sequentia Biotech has raised €10 million ($11 million) in a Series A round to finance the development of its omics-based technology for use in biomedicine, agritech and food.

Authenticx CPO Eric Prugh on the impact of AI technology in pharmacovigilance

Artificial intelligence has emerged as a potential solution to inconsistent reporting of adverse events, which to this day remains one of the main challenges in the field of pharmacovigilance.

Paid for and in partnership with Lonza Small Molecules

AI transforms route scouting for faster drug synthesis

Applying AI-enabled route scouting services allows drug developers to avoid pitfalls that can typically occur in drug synthesis, speeding up drug substance IND.

Pfizer withdraws sickle cell disease drug Oxbryta amid safety concerns

The US big pharma company Pfizer has voluntarily withdrawn the oral sickle cell disease treatment Oxbryta from the market and halted clinical trials of the drug as data indicate a high risk of severe adverse events.

AbbVie announces positive phase 3 results for Parkinson’s drug

Miplyffa bags FDA approval for ultra-rare disease

FDA greenlights first treatment for Niemann-Pick disease type C

The small molecule drug arimoclomol (Miplyffa) has got the green light from the U.S. Food and Drug Administration (FDA) for the treatment of the rare disease Niemann-Pick disease type C (NPC), which until now has lacked FDA-approved therapies.

Biohaven’s real-world trial shows positive results for spinocerebellar ataxia drug

The US biotech’s neurological drug candidate showed a reduction in disease progression of at least 50% and the company will now file with the FDA.

NuraBio closes $140m fundraising to develop neuroprotective drugs

The series A financing will enable Nura Bio to advance its lead drug candidate into the next stage of clinical trials, shortly after successfully completing a first phase 1 clinical trial.

Insilico Medicine claims phase 2 win for AI-designed drug

The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met its primary endpoint.

F2G raises $100 million to combat innovation 'paucity' in antifungals

One year after a rejection by the US Food and Drug Administration (FDA), the UK firm F2G has raised $100 million to push its candidate olorofim to the market for the treatment of rare fungal infections in 2026.

Boehringer Ingelheim score with phase 3 idiopathic pulmonary fibrosis win

The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.

uMotif expands site and patient platform with ClinOne acquisition

uMotif, a fast-growing company in the clinical research technology sector, has taken a significant step in expanding its platform with the acquisition of ClinOne, a provider of site platform solutions.

Innovative approaches to opioid use disorder treatment

As local and state governments in the US begin to receive and distribute their opioid settlement funds, Sonara Health has developed a comprehensive report analyzing how over $50 billion in national funds can be effectively allocated to address the opioid...